Table 3.
Renin–angiotensin–aldosterone system inhibitor therapy intensity at 3 months (intent‐to‐treat population)
| Number (%) of subjects | ||||||
|---|---|---|---|---|---|---|
| SZC (N = 92) | Placebo (N = 90) | |||||
| n = 58 | n = 49 | |||||
| Ranking of RAASi therapy intensity | ACEi/ARB/ARNI | MRA | ||||
| 0 | No dose | No dose | 2 | (3.4) | 2 | (4.1) |
| 1 | Some | No dose | 6 | (10.3) | 4 | (8.2) |
| 2 | No dose | Some | 0 | (0.0) | 0 | (0.0) |
| 3 | Target | No dose | 9 | (15.5) | 10 | (20.4) |
| 4 | Some | Some | 2 | (3.4) | 5 | (10.2) |
| 5 | No dose | Target | 1 | (1.7) | 0 | (0.0) |
| 6 | Target | Some | 2 | (3.4) | 3 | (6.1) |
| 7 | Some | Target | 14 | (24.1) | 8 | (16.3) |
| 8 | Target | Target | 22 | (37.9) | 17 | (34.7) |